Keep pulling the thread on Dario Amadei.
Moderna and Merck announced a successful stage 3 trial for a personalized mRNA cancer vaccine, the first late-stage trial of its kind to show promise.
The personalized cancer vaccine trial from Moderna and Merck was successful in more than 1,100 patients with advanced melanoma by extending their time in remission.
Moderna's stock increased by 70% after its cancer vaccine announcement and later reached 125% growth.
OpenAI is competing at the state-of-the-art with models like 5.6 SOL and the upcoming Astra, while also competing on efficiency with Luna against Chinese OpenWeight models.
Bloomberg reported that SpaceX approached the coding agent startup Cognition about a potential acquisition.
Cognition was most recently valued at $26 billion in May and is reportedly seeking a valuation of at least $40 billion in a new funding round.
Cognition CEO Scott Wu denied reports that the company is for sale or has been in acquisition talks with SpaceX.
The White House unveiled its new AI safety testing framework in a closed-door meeting attended only by staff from OpenAI, Anthropic, and Google.
Anthropic CEO Dario Amadei believes AI will win public trust by delivering tangible results, such as curing cancer, rather than through marketing campaigns.
Moderna and Merck are conducting similar trials for their personalized mRNA vaccine approach in lung cancer.
The personalized mRNA cancer treatment from Moderna and Merck uses AI to help identify which of a tumor's mutations are most likely to trigger an immune response.
OpenAI has introduced a safety technique called Private Safety Processing for eligible API customers with zero data retention agreements.